(0.25%) 5 112.54 points
(0.34%) 38 371 points
(0.30%) 15 976 points
(-1.34%) $82.73
(6.34%) $2.05
(-0.07%) $2 345.60
(-0.22%) $27.48
(3.93%) $958.35
(-0.22%) $0.933
(-0.33%) $10.99
(-0.54%) $0.796
(1.65%) $93.39
Live Chart Being Loaded With Signals
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight...
Stats | |
---|---|
Šios dienos apimtis | 441 032 |
Vidutinė apimtis | 331 386 |
Rinkos kapitalizacija | 30.93M |
EPS | €0 ( 2024-04-08 ) |
Kita pelno data | ( €0 ) 2024-05-15 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.620 |
ATR14 | €0.00500 (0.75%) |
Tūris Koreliacija
Poxel SA Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Poxel SA Koreliacija - Valiuta/Žaliavos
Poxel SA Finansinės ataskaitos
Annual | 2023 |
Pajamos: | €1.98M |
Bruto pelnas: | €1.98M (100.00 %) |
EPS: | €0 |
FY | 2023 |
Pajamos: | €1.98M |
Bruto pelnas: | €1.98M (100.00 %) |
EPS: | €0 |
FY | 2022 |
Pajamos: | €674 000 |
Bruto pelnas: | €2 000.00 (0.30 %) |
EPS: | €-1.080 |
FY | 2021 |
Pajamos: | €13.40M |
Bruto pelnas: | €13.34M (99.56 %) |
EPS: | €-0.830 |
Financial Reports:
No articles found.
Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.